Vantage logo

Key biotech catalysts approach

Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.

Vantage logo

Abbvie looks east for CD47

Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.

Vantage logo

CD47 is worth $4.9bn to Gilead

A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.

Vantage logo

Forty Seven bucks the trend

Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.